Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track DRMA with free AI briefings, catalyst countdowns, and dilution alerts.

DRMA · Dermata Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.8M Cash on Hand
5.7mo Cash Runway
Follow DRMA by email Get an email when DRMA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about DRMA, unsubscribe in one click. Privacy

📣 What DRMA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
DMT310 Acne Vulgaris Phase 3 · NCT06090721 Completed
DMT210 Topical Gel Atopic Dermatitis Phase 2 · NCT02949960 Completed
DMT210 Topical Gel 5% Acne Rosacea Phase 2 · NCT03003104 Completed
Topical Powder Acne Rosacea Phase 2 · NCT05108025 Unknown

Also used in these trials (approved or third-party drugs, not DRMA's own candidates): Hydrogen Peroxide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

DRMA holds $4.8M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.5M/quarter from operations, an estimated runway of 5.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 80 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when DRMA files for a raise →

👥 Who Owns DRMA

Insiders 24.5% Other 5%+ holders 8.4% Institutions (16 holders) 12.1% Public and other holders 55%
HolderTypeShares% of sharesAs of
Gerald T Proehl
President, CEO and Chairman, Director, 1 · +3.02M options
Insider 694,687 14.09% 2026-02-19
Bigger Michael 5%+ holder (13G) 414,064 8.40% 2026-09-30
Hoose Kyri K. Van
SVP, CFO · +573,793 options
Insider 232,463 4.72% 2026-08-16
Mary Fisher
Director · +214,351 options
Insider 196,946 3.99% 2025-01-21
David F Hale
Director · +96,241 options
Insider 81,469 1.65% 2025-01-21
Munera Maria E Bedoya-Toro
SVP, Regulatory Affairs · +17,000 options
Insider 1,046 0.02% 2026-02-17
Kathleen D. Scott
Director · +17,500 options
Insider 1 0.00% 2026-06-16

Share count 4,930,207 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full DRMA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for DRMA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.